HALf Of NEW CAN­CER DRUGS NOT SHOW­ING SUR­VIVAL GAINS

The Sunday Guardian - - Covert -

LONDON: Nearly half of new can­cer drugs ap­proved in Europe show lit­tle ev­i­dence that they are help­ing ex­tend or im­prove life, says a new study. Even where drugs did show sur­vival gains over ex­ist­ing treat­ments, these were of­ten mar­ginal, found the re­searchers based at King’s Col­lege London and the London School of Eco­nom­ics. The study pub­lished in the jour­nal BMJ prompts calls to “raise the ev­i­dence bar” for ap­proval of new can­cer drugs. Many of the drugs were ap­proved on the ba­sis of in­di­rect mea­sures that do not al­ways re­li­ably pre­dict whether a pa­tient will live longer or feel bet­ter, rais­ing se­ri­ous ques­tions about the cur­rent stan­dards of drug reg­u­la­tion.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.